BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
about
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
P2860
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
BRCA1-like profile predicts be ...... domized in the WSG-AM01 trial.
@en
type
label
BRCA1-like profile predicts be ...... domized in the WSG-AM01 trial.
@en
prefLabel
BRCA1-like profile predicts be ...... domized in the WSG-AM01 trial.
@en
P2093
P2860
P356
P1476
BRCA1-like profile predicts be ...... domized in the WSG-AM01 trial.
@en
P2093
Cornelia Liedtke
Enrico Pelz
Frederik Marme
Janneke Kruizinga
Marja Nieuwland
Markus Frick
Nadia Harbeck
Philip C Schouten
Raihana Diallo-Danebrock
P2860
P304
P356
10.1002/IJC.30078
P50
P577
2016-03-04T00:00:00Z